Clinical trial · Interventional
Pemetrexed and Cisplatin Treatment Before Surgery in Non Small Cell Lung Cancer
Alimta (Pemetrexed) and Cisplatin Treatment as Neoadjuvant Therapy in Non Small Cell Lung Cancer
NCT00259285CI-TRIAL-00002347terminatedPhase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Trial was stopped early due to low enrollment.
Summary
Brief summary (as posted)
To determine the response to this regimen for therapy prior surgery in patients with locally advanced disease or metastatic disease.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-Small-Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| cisplatin | Drug | Cisplatin | ALIAS |
| pemetrexed | Drug | Pemetrexed | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- A
- interventionNames
- Drug: pemetrexed
- Drug: cisplatin
Primary outcomes (1)
- measure
- Treatment Response
- timeFrame
- every 21 day cycle (3 cycles) and 3-4 weeks after last cycle
- description
- Best response recorded from the start of treatment until disease progression/recurrence using Response Evaluation Criteria In Solid Tumors (RECIST) criteria that defines when participants improve ("respond"), stay the same ("stable"), or worsen ("progression") during treatment.
Secondary outcomes (2)
- measure
- Pathologic Remissions After Surgery
- timeFrame
- surgical tumor resection (3-4 weeks after completing three 21-day cycles of therapy)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of non-small-cell carcinoma of the lung * Patients with locally advanced disease or metastatic disease, candidates to surgery after evaluation by oncologist and thoracic surgeon * Tumour with possibility of curative surgery * At least one uni-dimensionally measurable lesion * Adequate pulmonary function to perform the planned surgical resection Exclusion Criteria: * Active infection (at the investigator's discretion) * Pregnancy or breast-feeding * Serious concomitant illness at the investigator's discretion * Previous diagnosis of malignant disease * They have received treatment during the last 30 days with a drug, other than the study drug, that has not received regulatory approval for any indication at the time of their entry in the study
References
Publications (0)
Data not yet available
No reference posted for this study.